Annual report pursuant to Section 13 and 15(d)

Composition of Certain Financial Statement Captions Composition of Certain Financial Statement Captions (Details 3)

v2.4.0.8
Composition of Certain Financial Statement Captions Composition of Certain Financial Statement Captions (Details 3) (USD $)
In Thousands, unless otherwise specified
12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Sci Gen [Member]
Dec. 31, 2013
Cytochroma [Member]
Dec. 31, 2013
PROLOR [Member]
Aug. 29, 2013
PROLOR [Member]
Dec. 31, 2013
Pharmaceutical [Member]
MEXICO
Dec. 31, 2012
Pharmaceutical [Member]
MEXICO
Dec. 31, 2013
Pharmaceutical [Member]
CHILE
Dec. 31, 2012
Pharmaceutical [Member]
CHILE
Dec. 31, 2013
Pharmaceutical [Member]
CURNA [Member]
Dec. 31, 2012
Pharmaceutical [Member]
CURNA [Member]
Dec. 31, 2013
Pharmaceutical [Member]
Farmadiet [Member]
Dec. 31, 2012
Pharmaceutical [Member]
Farmadiet [Member]
Dec. 31, 2013
Pharmaceutical [Member]
FineTech [Member]
Dec. 31, 2012
Pharmaceutical [Member]
FineTech [Member]
Dec. 31, 2013
Pharmaceutical [Member]
Sci Gen [Member]
Dec. 31, 2012
Pharmaceutical [Member]
Sci Gen [Member]
Dec. 31, 2013
Pharmaceutical [Member]
Cytochroma [Member]
Dec. 31, 2012
Pharmaceutical [Member]
Cytochroma [Member]
Dec. 31, 2013
Pharmaceutical [Member]
PROLOR [Member]
Dec. 31, 2012
Pharmaceutical [Member]
PROLOR [Member]
Dec. 31, 2013
Diagnostics [Member]
Claros [Member]
Dec. 31, 2012
Diagnostics [Member]
Claros [Member]
Dec. 31, 2013
Diagnostics [Member]
Opko Diagnostics [Member]
Dec. 31, 2012
Diagnostics [Member]
Opko Diagnostics [Member]
Goodwill [Roll Forward]                                                    
Beginning balance $ 80,450 [1] $ 39,815 $ 760 $ 2,411 $ 139,784 $ 139,784 $ 114 $ 106 $ 6,697 $ 5,282 $ 4,827 $ 4,827 $ 8,712 $ 0 $ 11,698 $ 11,623 $ 796 $ 0 $ 0 $ 0 $ 0 $ 0 $ 17,977 $ 17,977 $ 29,629 $ 0
Acquisitions 142,195 38,739         0 0 0 0 0 0 0 8,313 0 0 0 796 2,411 0 139,784 0 0 0 0 29,629
Foreign exchange, other 3,729 1,896         0 8 (594) 1,415 0 0 363 399 0 74 943 0 (342) 0 0 0 0 0 3,359 0
Ending balance $ 226,373 [1] $ 80,450 [1] $ 760 $ 2,411 $ 139,784 $ 139,784 $ 113 $ 114 $ 6,102 $ 6,697 $ 4,827 $ 4,827 $ 9,075 $ 8,712 $ 11,698 $ 11,698 $ 1,740 $ 796 $ 2,069 $ 0 $ 139,784 $ 0 $ 17,977 $ 17,977 $ 32,988 $ 29,629
[1] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.